{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:56:41Z","timestamp":1784696201352,"version":"3.55.0"},"reference-count":27,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"\n BACKGROUND:<\/jats:title>\n Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high rates of treatment failure in adults. The epidemiology, clinical outcomes, and risk factors for treatment failure associated with MRSA bacteremia in children are poorly understood.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n Multicenter, retrospective cohort study of children \u226418 years hospitalized with MRSA bacteremia across 3 tertiary care children\u2019s hospitals from 2007 to 2014. Treatment failure was defined as persistent bacteremia &gt;3 days, recurrence of bacteremia within 30 days, or attributable 30-day mortality. Potential risk factors for treatment failure, including the site of infection, vancomycin trough concentration, critical illness, and need for source control, were collected via manual chart review and evaluated using multivariable logistic regression.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n Of 232 episodes of MRSA bacteremia, 72 (31%) experienced treatment failure and 23% developed complications, whereas 5 (2%) died within 30 days. Multivariable analysis of 174 children treated with vancomycin with steady-state vancomycin concentrations obtained found that catheter-related infections (odds ratio [OR], 0.36; 95% confidence interval [CI]: 0.13\u20130.94) and endovascular infections (OR, 4.35; 95% CI: 1.07\u201317.7) were associated with lower and higher odds of treatment failure, respectively, whereas a first vancomycin serum trough concentration &lt;10 \u03bcg\/mL was not associated with treatment failure (OR, 1.34; 95% CI, 0.49\u20133.66). Each additional day of bacteremia was associated with a 50% (95% CI: 26%\u201379%) increased odds of bacteremia-related complications.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n Hospitalized children with MRSA bacteremia frequently suffered treatment failure and complications, but mortality was low. The odds of bacteremia-related complications increased with each additional day of bacteremia, emphasizing the importance of achieving rapid sterilization.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2017-0183","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T09:10:13Z","timestamp":1493975413000},"source":"Crossref","is-referenced-by-count":58,"title":["Epidemiology of Methicillin-Resistant Staphylococcus aureus<\/i> Bacteremia in Children"],"prefix":"10.1542","volume":"139","author":[{"given":"Rana F.","family":"Hamdy","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Children\u2019s National Health System, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice J.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Stockmann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Primary Children\u2019s Hospital, Salt Lake City, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bryan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"},{"name":"Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Hersh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Gerber","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"},{"name":"Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"issue":"5","key":"2021121015092376300_B1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"13","key":"2021121015092376300_B2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2021121015092376300_B3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/427806","article-title":"Risk factors for hematogenous complications of intravascular catheter\u2013associated Staphylococcus aureus bacteremia.","volume":"40","author":"Fowler","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2021121015092376300_B4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies.","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"issue":"7","key":"2021121015092376300_B5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1086\/597521","article-title":"Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome.","volume":"30","author":"Burke","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"2021121015092376300_B6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1017\/ice.2014.91","article-title":"Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes.","volume":"36","author":"Klieger","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"2021121015092376300_B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/00365540500372846","article-title":"Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome.","volume":"38","author":"Khatib","year":"2006","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"2021121015092376300_B8","doi-asserted-by":"crossref","first-page":"e0127385","DOI":"10.1371\/journal.pone.0127385","article-title":"Staphylococcus aureus bloodstream infection and endocarditis\u2013a prospective cohort study.","volume":"10","author":"Le Moing","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"2021121015092376300_B9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2021121015092376300_B10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000436281.18687.0c","article-title":"No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates.","volume":"33","author":"Goldman","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021121015092376300_B11","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1128\/JCM.00407-09","article-title":"Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.","volume":"47","author":"Mason","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"3","key":"2021121015092376300_B12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021121015092376300_B13","author":"Centers for Disease Control and Prevention","year":"2012"},{"issue":"10","key":"2021121015092376300_B14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/ciu583","article-title":"Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.","volume":"59","author":"Kullar","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2021121015092376300_B15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1444-0903.2001.00029.x","article-title":"Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality.","volume":"31","author":"Hill","year":"2001","journal-title":"Intern Med J"},{"issue":"7","key":"2021121015092376300_B16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"2021121015092376300_B17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1473-3099(14)70876-X","article-title":"A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study.","volume":"14","author":"Yaw","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2021121015092376300_B18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/00365540802441711","article-title":"Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time.","volume":"41","author":"Khatib","year":"2009","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"2021121015092376300_B19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1128\/JCM.01949-09","article-title":"Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.","volume":"48","author":"Welsh","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"10","key":"2021121015092376300_B20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.","volume":"32","author":"Frymoyer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021121015092376300_B21","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure.","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2021121015092376300_B22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia.","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"3","key":"2021121015092376300_B23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000000991","article-title":"Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome.","volume":"35","author":"McNeil","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021121015092376300_B24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jpids\/pit076","article-title":"Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?","volume":"3","author":"Knoderer","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"2021121015092376300_B25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/jpids\/pis083","article-title":"Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive Staphylococcal infections.","volume":"2","author":"Chhim","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"2021121015092376300_B26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2015.05.018","article-title":"An 11,000-isolate same plate\/same day comparison of the 3 most widely used platforms for analyzing multidrug-resistant clinical pathogens.","volume":"83","author":"Nielsen","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"2021121015092376300_B27","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-0183\/1063943\/peds_20170183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-0183\/1063943\/peds_20170183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T04:38:26Z","timestamp":1639197506000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/139\/6\/e20170183\/38696\/Epidemiology-of-Methicillin-Resistant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,1]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2017-0183","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]},"article-number":"e20170183"}}